GlassScriptPhysician profile
Robert Phillip Meyer
NPI 1144670944
$19,315.47
in general payments reported to CMS, 2019-2025
51 companies · $3,872 in 2025
The $3,872 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,998 · 2022: $4,640 · 2023: $3,445 · 2024: $4,361 · 2025: $3,872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $6.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,670.94 |
| Education | $6.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,573.84 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $2,211.22 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,724.97 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,439.14 | 2021-2025 | Otezla, Repatha, Repatha |
| Esperion Therapeutics, INC. | $1,252.65 | 2021-2024 | Nexlizet, Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $895.93 | 2023-2025 | |
| Corcept Therapeutics | $689.36 | 2023-2025 | Korlym |
| Axsome Therapeutics, INC. | $684.55 | 2024-2025 | Auvelity |
| Abbvie INC. | $621.74 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $579.37 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $554.57 | 2021-2024 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $465.35 | 2024-2025 | Arexvy, Penmenvy, Shingrix |
| Si-Bone, INC. | $400.61 | 2021-2024 | |
| Mannkind Corporation | $373.03 | 2023 | Afrezza, V-Go |
| Inari Medical, INC. | $278.85 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $245.51 | 2022-2023 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $226.38 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $212.88 | 2022 | |
| Stryker Corporation | $210.87 | 2022-2023 | Mako |
| Cequr Corporation | $194.63 | 2022-2023 | Cequr Simplicity |
| Boston Scientific Corporation | $166.43 | 2023-2025 | Ams 700, Watchman Flx, Watchman Access System |
| Abbott Laboratories | $164.91 | 2022-2024 | Freestyle Libre 3, Proclaim |
| Zealand Pharma US, INC. | $156.39 | 2022 | |
| Genzyme Corporation | $149.92 | 2023 | |
| Inspire Medical Systems, INC. | $149.92 | 2024 | Inspire |
| Organogenesis INC. | $146.05 | 2023 | Puraply |
| Dexcom, INC. | $142.94 | 2022-2024 | Dexcom G6 Transmitter |
| Medtronic, INC. | $135.43 | 2023 | Interstim |
| Merck Sharp & Dohme LLC | $132.97 | 2021-2024 | Vaxneuvance |
| Biotronik Nro, INC. | $132.79 | 2024 | Prospera |
| Alkermes, INC. | $130.00 | 2025 | Lybalvi |
| Insulet Corporation | $129.99 | 2022 | |
| Lucid Diagnostics INC. | $127.14 | 2022 | |
| Janssen Pharmaceuticals, INC | $124.99 | 2021 | |
| Kyowa Kirin, INC. | $124.99 | 2024 | |
| Supernus Pharmaceuticals, INC. | $124.99 | 2021 | |
| Antares Pharma, INC. | $122.99 | 2022 | |
| Phathom Pharmaceuticals, INC. | $120.56 | 2025 | Voquezna |
| Radius Health, INC. | $120.55 | 2025 | Tymlos |
| Alnylam Pharmaceuticals INC. | $117.64 | 2023 | Amvuttra |
| Gilead Sciences, INC. | $116.71 | 2024 | Livdelzi |
| Neurocrine Biosciences, INC. | $114.07 | 2023 | |
| Neurelis, INC. | $103.45 | 2023 | Valtoco |
| Intuity Medical INC | $103.19 | 2022 | |
| Angiodynamics, INC. | $93.46 | 2025 | Auryon Laser System 100-120 Vac |
| Sanofi Pasteur INC. | $91.67 | 2022 | |
| Endologix LLC | $68.20 | 2025 | Torus Stent Graft System, Endocross Device |
| Lundbeck LLC | $19.24 | 2025 | Rexulti |
| Amarin Pharma, INC. | $16.60 | 2021 | |
| Coopersurgical, INC. | $16.04 | 2022 | |
| Exact Sciences Corporation | $15.80 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.